IDH1 and central nervous system cancer: Isocitrate dehydrogenase 1 (IDH1) mutation information is crucial for diagnosis, prognosis and guidance in clinical decisions due to observation that IDH1 mutated gliomas have an improved overall survival rate rather than with IDH1 wild type [64, 65].